Berman Capital Advisors’s CorMedix CRMD Stock Holding History

Berman Capital Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-340	Closed	-$2K	–	1693
2020 Q3	$2K	Hold	340	–	–	﹤0.01%	1270
2020 Q2	$2K	Buy	+340	New	+$1.57K	﹤0.01%	1251

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Berman Capital Advisors's CRMD Position: Q4 2020 in Review

Berman Capital Advisors sold out of CorMedix (CRMD) in Q4 2020, closing a stake of 340 shares — an estimated $2K sold.

Berman Capital Advisors first reported a position in CRMD in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 75 funds tracked by Wall St. Rank hold CRMD as of Q4 2020.

Berman Capital Advisors reported no remaining CorMedix position as of Q4 2020 after selling out during the quarter.
Berman Capital Advisors sold 340 CorMedix shares in Q4 2020, an estimated $2K.
Berman Capital Advisors first reported a position in CorMedix in Q2 2020 and held it in 2 quarters.
Berman Capital Advisors's CorMedix position peaked at $2K in Q3 2020.
75 funds tracked by Wall St. Rank held CorMedix as of Q4 2020.

Based on Berman Capital Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.